EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- December 2022
has subject area
- 1117 Public Health and Health Services (FoR)
- 1402 Applied Economics (FoR)
- Health Policy & Services (Science Metrix)
published in
- Value in Health Journal